You are here:HomePharma

Pharma

  • Ranbaxy Forfeits 180 Days Exclusivity for Stomach Drugs

    Ranbaxy Forfeits 180 Days Exclusivity for Stomach Drugs

    Drug major Ranbaxy on Tuesday said that the US Food and Drug Administration or FDA has "determined" that the Indian drug manufacturer has forfeited its 180 days exclusivity for stomach and esophagus problems treatment tablets.

  • Aurobindo Pharma to Raise $350 Million Through QIP

    Aurobindo Pharma to Raise $350 Million Through QIP

    The board had earlier constituted a securities issue committee comprising of five board members, including two independent directors, for issue of securities.

  • Price Performance of Pharma StocksOther Stories
  • Aurobindo, Actavis Recall Gabapentin Capsules

    Aurobindo, Actavis Recall Gabapentin Capsules

    According to notification by the US Food and Drug Administration (USFDA), the Indian firm's arm Aurobindo Pharma USA Inc has initiated a Class II nation wide recall. Each bottle contains 100 capsules of 300 mg.

  • Novartis to Close Manufacturing Plant in Puerto Rico by 2019

    Novartis to Close Manufacturing Plant in Puerto Rico by 2019

    Novartis AG is closing its manufacturing plant in Puerto Rico as part of a major overhaul of its business.

  • Cipla Promoters Firm Buys Out Minority Investors in Okasa

    Cipla Promoters Firm Buys Out Minority Investors in Okasa

    Hamsons, a firm owned by the promoter family of pharmaceuticals major Cipla, has bought out the remaining 21 per cent equity owned by minority shareholders in Satara-based Okasa Pharma for an undisclosed amount, completing the process it started last September.

  • Gilead's Hepatitis C Drug Patent Request Rejected

    Gilead's Hepatitis C Drug Patent Request Rejected

    India's patent office has rejected an application from US-based Gilead Sciences Inc for its hepatitis C drug Sovaldi, paving the way for local drug makers to launch cheaper generic versions of the $1,000-a-pill medicine.

  • Novartis Gets Court Notice on Cipla Plea

    Novartis Gets Court Notice on Cipla Plea

    A bench of justices Badar Durrez Ahmed and Sanjeev Sachdeva, however, refused to pass any interim order to allow Cipla to manufacture its Indacaterol-based drug saying, it will give an early hearing to the matter.

  • Court Order Restraining Drug Sale Disappointing: Cipla

    Court Order Restraining Drug Sale Disappointing: Cipla

    Cipla has expressed disappointment over a Delhi High Court order restraining the drug maker from manufacturing and selling any medicine containing 'Indacaterol', saying that the interim verdict would deny patients access to the drugs they need.

  • Cipla Restrained From Selling Obstructive Pulmonary Disease Treatment Drug

    Cipla Restrained From Selling Obstructive Pulmonary Disease Treatment Drug

    The Delhi High Court on Friday temporarily restrained Cipla from manufacturing, importing or selling any drug containing the chemical Indacaterol which is used for treatment of chronic obstructive pulmonary disease (COPD) till it obtains a compulsory licence for the medicine.

  • Cadila Recalls 19,536 Bottles of Cough Treatment Drug in US

    Cadila Recalls 19,536 Bottles of Cough Treatment Drug in US

    Drug firm Cadila Healthcare is voluntarily recalling 19,536 bottles of benzonatate capsules, used to treat cough, in the US due to "wet and/or leaking capsules".

  • Wockhardt, Cadila, Hospira Recall Drugs in US

    Wockhardt, Cadila, Hospira Recall Drugs in US

    Drug firms Wockhardt, Cadila Healthcare and Hospira are voluntarily recalling certain lots of drugs in the US, according to the US Food and Drug Administration (FDA).

  • Lupin Gets Regulatory Nod to Market HIV Drug in US

    Lupin Gets Regulatory Nod to Market HIV Drug in US

    Drug firm Lupin has received a tentative approval from the US Food and Drug Administration (FDA) to market a generic version of Prezista tablets used in treating HIV infection.

  • 2014: Pharma Deals Worth Billions, Fines Worth Millions

    2014: Pharma Deals Worth Billions, Fines Worth Millions

    It has been a year of bitter medicine for Indian pharmaceutical companies with fines worth millions of dollars imposed by various foreign regulators, even as they stitched together deals worth billions of dollars, including a high profile merger between Sun Pharma and Ranbaxy.

  • Lupin Gets US Regulator's Nod for HIV Drug

    Lupin Gets US Regulator's Nod for HIV Drug

    Drug major Lupin has received approval of the US Food and Drug Administration (FDA) to market a generic version of ViiV Healthcare's 'Epivir' tablets, used in treating HIV infection, in the American market. Shares in Lupin rose nearly 1 per cent during the day.

  • Medical Devices Sector Welcomes 100% FDI

    Medical Devices Sector Welcomes 100% FDI

    Medical device makers on Wednesday welcomed the government's decision to allow up to 100 per cent foreign direct investment or FDI in the sector under automatic route, saying the move would boost technology inflow and manufacturing.

  • FDI Norms Eased for Medical Device Makers

    FDI Norms Eased for Medical Device Makers

    The government has made it easier for foreigners to fully own existing medical device makers in India, in a bid to boost investment in the $7-billion sector.

  • Novartis India Gains 5% as CCI Clears Deal with GSK

    Novartis India Gains 5% as CCI Clears Deal with GSK

    The multi-layered deal involves UK-based GlaxoSmithKline (GSK) acquiring the Swiss major's vaccine business while the latter would purchase GSK's cancer drugs portfolio.

  • Novartis-GSK Pharma Deal Cleared by CCI

    Novartis-GSK Pharma Deal Cleared by CCI

    The Competition Commission of India (CCI) has approved a multi-billion dollar deal between global pharma giants GlaxoSmithKline Plc and Novartis, as it does not find the transaction to be anti-competitive in India.

  • Merck Unit Sells Consumer Care Business to Bayer

    Merck Unit Sells Consumer Care Business to Bayer

    Fulford India, a Merck & Co Inc subsidiary, has transferred its consumer care business to Bayer Pharmaceuticals Private Ltd.

  • Dr Reddy's Acquires Habitrol Brand

    Dr Reddy's Acquires Habitrol Brand

    City-based drug maker Dr Reddy's Laboratories has acquired Habitrol brand, a nicotine replacement therapy transdermal patch, from Novartis Consumer Health Inc.

Social Sharing

Advertisement

Advertisement

Portfolio

Advertisement

Market Data provided by © Accord Fintech.
© Copyright NDTV Convergence Limited 2015. All rights reserved.